Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Carrier

Showing results (371-380 of 422) with videos related to

Pageof 43
Sort By:
Blood Advances|June 9, 2022
Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolismPhilip S Wells, Tobias Tritschler, Faizan Khan, et al.
Transplantation and Cellular Therapy|January 2, 2026
Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence from Machine Learning and Regression ModelsAshish Narayan Masurekar, Kelly M Burkett, Arya Rahgozar, et al.
JAMA Cardiology|November 12, 2025
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical TrialDeborah M Siegal, Christian Sticherling, Jeff S Healey, et al.
Journal of Thrombosis and Haemostasis : JTH|August 6, 2025
Racial Disparities in the Incidence and Risk Factors for Major Bleeding during Extended Anticoagulant Therapy for Venous ThromboembolismDuale Omar, Michael J Kovacs, Alejandro Lazo-Langner, et al.
Journal of Thrombosis and Haemostasis : JTH|August 29, 2021
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxabanFloris T M Bosch, Frits I Mulder, Menno V Huisman, et al.
Journal of Biomedical Informatics|May 18, 2023
A community-of-practice-based evaluation methodology for knowledge intensive computational methods and its application to multimorbidity decision supportWilliam Van Woensel, Samson W Tu, Wojtek Michalowski, et al.
The New England Journal of Medicine|December 13, 2017
Edoxaban for the Treatment of Cancer-Associated Venous ThromboembolismGary E Raskob, Nick van Es, Peter Verhamme, et al.
Research and Practice in Thrombosis and Haemostasis|January 3, 2022
Randomized trials of therapeutic heparin for COVID-19: A meta-analysisMichelle Sholzberg, Bruno R da Costa, Grace H Tang, et al.
Blood Advances|April 19, 2022
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort studyWalter Ageno, Jan Beyer Westendorf, Laura Contino, et al.
Annals of Internal Medicine|June 5, 2013
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trialDavid R Anderson, Michael J Dunbar, Eric R Bohm, et al.
Pageof 43

Showing results (371-380 of 422) with videos related to

Sort By:
Pageof 43
Blood Advances|June 9, 2022
Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolismPhilip S Wells, Tobias Tritschler, Faizan Khan, et al.
Transplantation and Cellular Therapy|January 2, 2026
Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence from Machine Learning and Regression ModelsAshish Narayan Masurekar, Kelly M Burkett, Arya Rahgozar, et al.
JAMA Cardiology|November 12, 2025
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical TrialDeborah M Siegal, Christian Sticherling, Jeff S Healey, et al.
Journal of Thrombosis and Haemostasis : JTH|August 6, 2025
Racial Disparities in the Incidence and Risk Factors for Major Bleeding during Extended Anticoagulant Therapy for Venous ThromboembolismDuale Omar, Michael J Kovacs, Alejandro Lazo-Langner, et al.
Journal of Thrombosis and Haemostasis : JTH|August 29, 2021
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxabanFloris T M Bosch, Frits I Mulder, Menno V Huisman, et al.
Journal of Biomedical Informatics|May 18, 2023
A community-of-practice-based evaluation methodology for knowledge intensive computational methods and its application to multimorbidity decision supportWilliam Van Woensel, Samson W Tu, Wojtek Michalowski, et al.
The New England Journal of Medicine|December 13, 2017
Edoxaban for the Treatment of Cancer-Associated Venous ThromboembolismGary E Raskob, Nick van Es, Peter Verhamme, et al.
Research and Practice in Thrombosis and Haemostasis|January 3, 2022
Randomized trials of therapeutic heparin for COVID-19: A meta-analysisMichelle Sholzberg, Bruno R da Costa, Grace H Tang, et al.
Blood Advances|April 19, 2022
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort studyWalter Ageno, Jan Beyer Westendorf, Laura Contino, et al.
Annals of Internal Medicine|June 5, 2013
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trialDavid R Anderson, Michael J Dunbar, Eric R Bohm, et al.
Pageof 43